Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.

Background DCV-TRIO, a fixed-dose combinationof daclatasvir(pangenotypic NS5Ainhibitor), asunaprevir( NS3/4A protease inhibitor), and beclabuvir(non-nucleoside NS5Binhibitor), has achieved high rates of sustained virologicresponse at post-treatment Week 12 (SVR12) in phase 3 studies.